Compare SOLS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | KRYS |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | SOLS | KRYS |
|---|---|---|
| Price | $48.58 | $232.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $54.00 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 2.8M | 294.2K |
| Earning Date | 02-03-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | 2.07 | ★ 6.66 |
| Revenue | ★ $3,812,000,000.00 | $373,164,000.00 |
| Revenue This Year | $3.34 | $36.14 |
| Revenue Next Year | $3.80 | $41.80 |
| P/E Ratio | ★ $23.57 | $35.39 |
| Revenue Growth | 4.47 | ★ 54.51 |
| 52 Week Low | $40.43 | $122.80 |
| 52 Week High | $61.00 | $248.60 |
| Indicator | SOLS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 62.35 |
| Support Level | N/A | $213.83 |
| Resistance Level | N/A | $248.60 |
| Average True Range (ATR) | 0.00 | 7.39 |
| MACD | 0.00 | -0.39 |
| Stochastic Oscillator | 0.00 | 56.86 |
Solstice Advanced Materials is a global specialty materials company advancing science to deliver smarter, more sustainable outcomes. The company provides high-performance solutions that support critical industries and applications, including refrigerants, semiconductor manufacturing, data center cooling, nuclear power, protective fibers, and healthcare packaging. Its brands include: Solstice, Genetron, Aclar, Spectra, Fluka, and Hydranal.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.